GLP-1 maintenance dosing: What 'lowest dose possible' actually means

What did @drkaisrona actually say?

Dr. Roana, a self-described weight loss specialist and surgeon, laid out her approach to GLP-1 maintenance dosing. The core argument: stopping cold turkey risks regaining about 60% of lost weight, individual responses vary widely, and the goal should be finding the lowest effective dose at the lowest possible frequency. She also flagged that these medications are new enough that even physicians are still learning.

She was careful to avoid specific dosing recommendations, which is worth noting. Instead she pushed patients toward working directly with their providers. That's a reasonable position. She also acknowledged that GLP-1 prescribing is still partly trial and error, which is a more honest framing than most social media content in this space offers. No miraculous cure claims, no dramatic before-and-after promises. The bar on TikTok is low, but she clears it.

Does the science back this up?

On the weight regain figure, yes, mostly. The 60% number is real and well-documented, though the full picture is a bit more complicated than a single statistic suggests.

The landmark STEP 1 trial extension (Wilding et al., 2022, New England Journal of Medicine) followed patients who stopped semaglutide after 68 weeks. Within one year of stopping, participants regained about two-thirds of their prior weight loss on average. A separate analysis of tirzepatide discontinuation from the SURMOUNT-4 trial (Aronne et al., 2024, JAMA) found that patients who switched to placebo after 36 weeks of tirzepatide regained significant weight compared to those who continued. The regain data across GLP-1 agents is consistent: these medications require ongoing use to sustain effect for most people.

The individualized dosing argument also has support. A 2023 analysis in Obesity Reviews noted substantial inter-individual variability in GLP-1 receptor agonist response, driven by factors including gut microbiome composition, receptor expression, and baseline metabolic rate. There is no validated formula for predicting who will respond well to what dose.

What did they get right, and where are the gaps?

Dr. Roana got the big things right. The regain risk is real. Individualization matters. The medications are relatively new and the long-term maintenance literature is thin. Giving credit where it is due: this is a more responsible framing than most GLP-1 content circulating on TikTok right now.

That said, a few gaps are worth naming. The phrase "lowest dose possible at the lowest frequency possible" is intuitive but not yet evidence-based as a formal maintenance strategy. There are no large published trials comparing, say, monthly versus weekly dosing as a maintenance protocol for weight stability. Physicians are making reasonable clinical judgments, but patients should know that "lowest dose" maintenance is a working hypothesis, not a proven protocol.

She also mentions diet and exercise as the foundation of every maintenance plan, which is accurate in principle. But the STEP trials consistently showed that lifestyle intervention alone produces far less weight loss than medication plus lifestyle. Framing food and exercise as the foundation without acknowledging how dramatically these medications change appetite signaling can give patients an unrealistic picture of what happens if the drug is tapered too quickly.

What should you actually know?

GLP-1 medications work for weight management in a majority of users, but they are not a course of treatment with a defined endpoint for most people. The biology is clear: when you stop, appetite-regulating hormones shift back, and weight returns for most patients. That is not a personal failure. It is pharmacology.

If you are considering a maintenance taper, the honest answer is that the field does not yet have a gold-standard protocol. Providers like Dr. Roana are drawing on clinical experience and extrapolating from trial data, which is legitimate but carries uncertainty. The advice to work closely with your provider is not a platitude here. It is the correct answer given how little the published evidence covers real-world maintenance scenarios.

One more thing: compounded GLP-1 formulations, which many telehealth patients use, have not been studied in the same maintenance trials as brand-name drugs like Wegovy or Zepbound. Dose and frequency findings from those trials do not automatically transfer. That distinction matters when evaluating any maintenance guidance.